Pharmaceutical

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Disease): Likelihood of Approval

UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).

Dec 20, 2023 - 18:00
UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

GUB-014295 by Gubra for Obesity: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Getting rid of bias in clinical calculators isn’t as simple as taking race out of the equation

STAT+: Getting rid of bias in clinical calculators isn’...

Jun 20, 2023

UPFs fuelling ‘alarming rise of chronic diseases’ in india

UPFs fuelling ‘alarming rise of chronic diseases’ in india

Oct 30, 2024

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

AstraZeneca mulls risk strategy for Ultomiris following...

Sep 7, 2023